Kalray Wins Flash Memory Summit Award for the Second Year in a Row
10.8.2023 17:48:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for the high-performance, data-centric computing and storage markets, has been recognized as the leader of the DPU category in the 17th Annual Flash Memory Summit Awards competition.
Flash Memory Summit (FMS) is the world’s largest international comprehensive memory and storage showcase, hosted at the Santa Clara Convention Center, California, USA. The new Kalray K220-LP Storage Acceleration Card, powered by Kalray's 3rd generation DPU processor, won the FMS Award in the DPU category. This Flash Memory Summit Award symbolizes the industry's acknowledgment of the innovation and business value that Kalray solutions bring to the market.
KALRAY UNVEILS ITS NEW K220-LP™ SMART STORAGE ACCELERATOR
Kalray’s K220-LP™ Smart Storage Accelerator (SSA) was introduced at FMS this year, bringing storage offload to the next level. By offloading intensive storage data services from the main CPU, the SSA releases all the potential of NVMe SSDs in any server with local NVMe devices. The main CPU is freed to perform billable tasks while all storage-related tasks are offloaded to the Kalray K220-LP™ Smart Storage Accelerator.
“Customers have a need to maximize their server investments by pursuing greater optimization and performance. This can be achieved by offloading storage data services to specialized processors for maximum ROI of the server infrastructure,” said Jay Kramer, chairman of the awards program and president of Network Storage Advisors Inc. “We are proud to recognize Kalray’s Smart Storage Accelerators for their ability to efficiently store both data and metadata on storage class memory (SCM) while offloading storage data services and applications from the main CPU. This solution enables customers to realize the full potential of local NVMe SSDs deployed in any industry-standard server.”
KALRAY DEMONSTRATES THAT QLC MEMORY ADOPTION BENEFITS DATA CENTERS
As a powerful use case, Kalray demonstrated how its solution allows a new generation of SSDs, called QLC SSDs, to be adopted into data centers without requiring any changes to the data center operating system, file system, or applications. Kalray DPUs have accelerators, fast coherent memory, and flexible programmability, which makes them ideal for storage management functions such as managing new QLC technology. Thanks to Kalray’s solution, data centers can take full advantage of the price, capacity, and performance benefits of QLC flash devices. The result is a data center that realizes the benefits of QLC without performance and durability penalties and without the need to modify existing software.
“QLC SSDs present great economic advantages by delivering greater capacity and density. But compared to other SSD types, QLC technology has challenges to overcome, including lower endurance, higher latency, and reduced performance under heavy workloads,” added Jay Kramer. “We are proud to recognize Kalray’s Smart Storage Accelerators for their highly effective performance in enabling a simple deployment on industry-standard servers. This solution allows customers to achieve cost and capacity benefits of QLC devices transparently, with no hardware architectural changes and no software stack changes.”
ACKNOWLEDGEMENT OF THE SOLUTION’S INNOVATION
“It is a great honor to win a Flash Memory Summit award for the second year in a row,” said Éric Baissus, chief executive officer of Kalray. “This award represents strong recognition of the value of our solutions. Customers who integrate our new K220-LP™ SSA into their servers can accelerate the transition from traditional storage architectures relying on SAS (Serial Attached SCSI) to high-performance, power-efficient NVMe-based solutions.”
The K220-LP™ solution includes Kalray’s AccessCore® Storage (ACS) software SDK. Thanks to ACS SDK, the K220-LP™ SSA is fully programmable, enabling offload of custom storage or computational application processing, thus removing the usual bottlenecks of traditional architectures. The Kalray solution enables data centers to leapfrog outdated technologies that are unable to sustain the storage requirements of demanding workloads and embrace the benefits of modern, scalable, and flexible data solutions with minimal effort.
This is the second consecutive award Kalray has received from Flash Memory Summit, maintaining momentum in innovation following last year’s award for most innovative technology with Flashbox™.
ABOUT KALRAY
Kalray (Euronext Growth Paris – FR0010722819 – ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Kalray’s offerings include unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as leading-edge software-defined storage and data management solutions. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers and to design the best solutions in fast-growing sectors such as AI, media & entertainment, life science, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. Visit us at www.kalrayinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809063602/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS finance & communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Tel. 01 53 67 36 72
PRESS
Diana EADINGTON
communication@kalrayinc.com
Tel. +44 7939 877 880
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
